I view Pro Medicus Ltd (ASX: PME) as one of Australia's top shares, and I think there are a number of great reasons to consider owning the ASX share.
Pro Medicus provides a full range of medical imaging software and services to hospitals, imaging centres, and healthcare. It has revolutionised the industry of radiology information systems (RIS) and picture archiving and communication systems (PACS).
In the past year, the Pro Medicus share price is down 28%, at the time of writing (as the above chart shows). But I think it could fall further today/this week after significant volatility on the US share market on Friday – the NASDAQ-100 Index (NASDAQ: NDX) fell 5.6% in one day.
I think this period could be a rare opportunity to buy one of Australia's top shares.

Image source: Getty Images
Excellent contract wins
A key driver for a company's success is its revenue growth because that's the start of the profit waterfall to get to the net profit after tax (NPAT).
Regardless of what's happening with the Pro Medicus share price, the company's underlying financials are growing at a rapid pace.
In FY26 alone (reported in August), the business announced 22.9% revenue growth to $261.7 million. During FY26, it signed 10 new contracts worth a minimum of A$407 million, which will help drive revenue in future financial years.
The healthcare tech company has already announced a number of wins since the start of FY27. The latest win was huge: it signed a 10-year A$128 million contract with NYC Health + Hospitals. It was a transaction-based model with potential upside for its full stack of Visage 7 software offerings.
Since the beginning of FY27, it has also signed an A$43 million, seven-year contract with Virtua Health, an A$24 million, seven-year contract with Billings Clinic, an A$25 million contract with Valley Health, and an A$23 million seven-year contract with St Luke's Health.
That's a lot of new contracts and significant revenue to come online during FY27 and FY28.
How many other Australian businesses have managed to win so strongly in the US, the supposed home of innovation? This alone shows it's one of Australia's top shares, in my view.
Rising profit
As a software business, Pro Medicus is able to deliver enormous profit margins. It has one of the highest operating profit margins on the ASX.
In FY26, the business reported an EBIT margin (operating profit) of 74.9%, up 90 basis points (0.90%). The fact that it keeps rising is very impressive, and I believe it'll keep rising for the foreseeable future thanks to its growing contract base.
In constant currency terms, the underlying revenue grew 28.4% to $273.5 million, and underlying net profit grew 32.5%, demonstrating both rapid growth and strengthening margins.
According to the profit projection on CommSec, the Pro Medicus share price is valued at 103 times FY27's estimated earnings, with forecast earnings per share (EPS) growth of 24% in FY28 and 26.5% profit growth in FY29. In other words, it's projected to keep growing earnings at a fast pace for the foreseeable future.
Great dividend growth
Its dividend yield is very low because of that high price-to-earnings (P/E) ratio. But shareholder payouts are rapidly increasing, and that is helping the bank account feel the fruits of the earnings growth, rather than having to sell.
According to CommSec, the annual dividend per share is projected to grow by 34% in FY27 to 92.5 cents, with further growth of 24% in FY28 and 26.5% growth in FY29. In other words, the annual payout could increase by 110% between FY26 and FY29.
However, even with all that growth, the Pro Medicus FY29 dividend yield would only be around 0.8% excluding franking credits and 1.1% with franking credits (at a Pro Medicus share price of $187.76).
Overall, there's a lot to like about this business, which I'm calling one of Australia's top shares. I think it's a solid long-term buy and could get even cheaper.